Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study

Απλή σελίδα τεκμηρίου
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorAgnantis, N. J.en
dc.contributor.authorZagorianakou, P.en
dc.contributor.authorKamina, S.en
dc.contributor.authorGorezi, M.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorBai, M.en
dc.date.accessioned2015-11-24T19:02:34Z
dc.date.available2015-11-24T19:02:34Z
dc.identifier.issn0392-9078-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19814
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast Neoplasms/drug therapy/mortality/*pathology/surgeryen
dc.subjectChemotherapy, Adjuvanten
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectPredictive Value of Testsen
dc.subjectPrognosisen
dc.subjectProto-Oncogene Proteins c-bcl-2/*analysisen
dc.subjectRetrospective Studiesen
dc.subjectSurvival Rateen
dc.subjectTime Factorsen
dc.subjectTreatment Outcomeen
dc.titleNear-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological studyen
heal.abstractThe clinical relevance of quantitative assessment of tumor-tissue expression of the bcl-2 protein in operated stage II breast cancer was investigated in this study. Thirty-five cases were studied by immunohistochemistry for the expression of bcl-2 protein and analyzed for disease outcome. One fourth (25%) of the cases were negative and 57% demonstrated near-absolute expression of the bcl-2 protein. No association was found between immunohistochemical detection of the protein with age, hormonal receptor status and tumor grading other than between bcl-2 and estrogen receptor expression (p=0.01). An impressively positive impact of near-absolute expression of bcl-2 on clinical outcome was identified. Our results provide evidence that quantitative assessment of bcl-2 expression constitutes a new approach in early breast cancer with potential clinical implications. We consider that molecular sub-staging of patients with stage II breast cancer by level of bcl-2 expression provides additional important prognostic information and prompts for investigation of its clinical significance on the issue of adjuvant systemic therapy.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11718212-
heal.journalNameJ Exp Clin Cancer Resen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2001-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ